Reuters Health
NEW YORK (Reuters Health) – People in most need of sight-preserving eyedrops may be the least successful in landing the therapy in their eyes, suggests a new study.
Buildup of internal eye pressure is one of the main causes of the vision damage associated with glaucoma, a potentially blinding disease that affects more than 4 million Americans, according to the Glaucoma Research Foundation. Standard treatment relies on self-administering pressure-lowering eyedrops.
But based on observations of a large number of people with glaucoma, researchers found that more than half struggled to apply these eyedrops properly -- including many patients who thought their technique was perfect.